SBP 103 - Spark BioPharma
Alternative Names: SBP103 - Spark BioPharmaLatest Information Update: 29 Jan 2022
At a glance
- Originator Spark BioPharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 14 Dec 2021 Early research in Solid tumours in South Korea (unspecified route) before December 2021 (Spark Biopharma pipeline, December 2021)